02214nas a2200313 4500000000100000008004100001260004600042653001000088653002200098653001100120653001100131653001200142653000900154653001600163653001900179100001300198700001600211700001600227700001400243700001600257700002000273700001600293245005500309856006000364300001200424490000700436520144300443022001401886 2012 d c2012 Sep 01bMedicina Oral S.L.aValencia10aAdult10aFacial Dermatoses10aFemale10aHumans10aleprosy10aMale10aMiddle Aged10aMouth Diseases1 aTaheri J1 aMortazavi H1 aMoshfeghi M1 aBakhshi M1 aBakhtiari S1 aAzari-Marhabi S1 aAlirezaei S00aOro-facial manifestations of 100 leprosy patients. uhttp://www.medicinaoral.com/medoralfree01/aop/17718.pdf ae728-320 v173 a
OBJECTIVES: To verify the frequency of oral and facial involvement in diagnosed leprosy patients.
STUDY DESIGN: This study was performed on 100 leprosy patients (62 male, 38 female, mean ages 51.86±6.1). After explaining the study design, we studied descriptive information including: patient' s sex, age, job, place of birth, familial history of leprosy, types of disease (lepromatous, borderline and tuberculoid leprosy), ocular and oral lesions, facial involvement and neuropathy. The statistical signification was measured by chi-square test.
RESULTS: A total of 46 (23 lepromatous, 15 borderline, and 8 tuberculoid leprosy) out of 100 patients with leprosy had oral lesions. Statistical analysis did not show any significant difference in frequency of oral lesions between different types of disease. Facial lesions were presented in 57 (39 lepromatous, 10 borderline, and 8 tuberculoid leprosy) patients. There was a statistical significant difference in frequency of facial manifestations between different types of leprosy. It has to be mentioned that, atrophy of nasal spine, facial nerve involvement, ocular lesions and facial deformity were seen in 15%, 17%, 22% and 44% of leprosy patients, respectively.
CONCLUSION: Examination of leprosy patients should be extended to the oral mucosa because oral mucosa may be a secondary source of M.Leprae transmission and infection.
a1698-6946